Segment Information - Schedule of Reconciliation to the Consolidated Net Loss (Details) - USD ($) |
3 Months Ended | 6 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
| Reconciliation of net loss | ||||||||||
| Change in fair value of warrant liabilities | $ 20,624 | $ (8,436) | $ 1,562,756 | $ 68,431 | ||||||
| Realized foreign currency translation loss from dissolution of subsidiaries | (7,171) | |||||||||
| Foreign currency gain/(loss) | (29,792) | 29,290 | (39,283) | 29,290 | ||||||
| Other income | 38,182 | 19,464 | 62,365 | 19,464 | ||||||
| Interest and dividends, net | 410,416 | 54,424 | 860,754 | 101,669 | ||||||
| Segment and consolidated net loss | 5,273,852 | $ 2,869,482 | 3,716,157 | $ 3,563,238 | 8,143,334 | 7,279,395 | ||||
| Reporting Segment [Member] | ||||||||||
| Schedule of Reconciliation to the Consolidated Net Loss [Line Items] | ||||||||||
| General and administrative | [1] | 1,584,064 | 1,460,723 | 3,224,150 | 3,157,148 | |||||
| Pre-clinical research | [1] | 57,436 | 103,343 | 431,797 | 165,336 | |||||
| Non-clinical research | [1] | 401,266 | 401,266 | |||||||
| CMC | [1] | 955,875 | 99,413 | 1,614,273 | 324,010 | |||||
| Clinical development | [1] | 2,227,156 | 1,928,275 | 4,134,232 | 3,363,079 | |||||
| Depreciation and amortization | 157,541 | 161,746 | 315,082 | 323,454 | ||||||
| Share based compensation expense | 329,944 | 57,645 | 469,126 | 156,203 | ||||||
| Other segment items | [2] | (246) | 1,848 | |||||||
| Total operating and segment expenses | 5,713,282 | 3,810,899 | 10,589,926 | 7,491,078 | ||||||
| Reconciliation of net loss | ||||||||||
| Change in fair value of warrant liabilities | 20,624 | (8,436) | 1,562,756 | 68,431 | ||||||
| Realized foreign currency translation loss from dissolution of subsidiaries | (7,171) | |||||||||
| Foreign currency gain/(loss) | (29,792) | 29,290 | (39,283) | 29,290 | ||||||
| Other income | 38,182 | 19,464 | 62,365 | 19,464 | ||||||
| Interest and dividends, net | 410,416 | 54,424 | 860,754 | 101,669 | ||||||
| Segment and consolidated net loss | $ 5,273,852 | $ 3,716,157 | $ 8,143,334 | $ 7,279,395 | ||||||
| ||||||||||
| X | ||||||||||
- Definition The amount of cmc. No definition available.
|
| X | ||||||||||
- Definition Amount of clinical development. No definition available.
|
| X | ||||||||||
- Definition Represents the amount of non-clinical research. No definition available.
|
| X | ||||||||||
- Definition The amount of operating and segment expenses. No definition available.
|
| X | ||||||||||
- Definition The amount of pre-clinical research. No definition available.
|
| X | ||||||||||
- Definition Amount, after tax, of expense for award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income related to nonoperating activities, classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|